Company intelligence / Profile preview

Omniscope

Dover, Delaware, USA

Ownership: Private
Development stage: Other

Overview

Clinical results are not published as traditional drug/therapeutic, but Omniscope’s technology is being applied in service contracts and partnerships for deep immune profiling and diagnostics; scientific papers and posters presented in 2025 indicate active validation and utility in leading academic and clinical centers

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: DiagnosticsData analytics platform (genomics and immune profiling)Immunoprofiling (primarily for T cell and adaptive immune system analysis)
Industry: Molecular Diagnostics

Partnerships

Collaborations with Spanish National Centre for Genomic Analysis (CNAG) and LifeTime InitiativeScientific engagement with Human Cell Atlas project

Beyond the preview

Go deeper on Omniscope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omniscope.

Explore the full profile